Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab
The expression of the immune checkpoint molecule CTLA-4 has been almost exclusively
studied in the T cell lineage, but increasing evidence has shown its expression on tumors …
studied in the T cell lineage, but increasing evidence has shown its expression on tumors …
CTLA-4 in regulatory T cells for cancer immunotherapy
Simple Summary In the fight against cancer, immunotherapies have given great hope after
encouraging results in clinical investigations showing complete remission in some patients …
encouraging results in clinical investigations showing complete remission in some patients …
Monoclonal antibodies to CTLA-4 with focus on ipilimumab
The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 or CD152) is
a negative regulator of T-cell-mediated immune responses which plays a critical role in …
a negative regulator of T-cell-mediated immune responses which plays a critical role in …
Expression and function of CTLA4 in melanoma.
B Seliger, M Maio, O Cuaia, L Calabro - 2013 - ascopubs.org
e20040 Background: The definition of co-inhibitory molecules negatively interfering with
immune responses has provided novel targets for therapeutic intervention. These include …
immune responses has provided novel targets for therapeutic intervention. These include …
[PDF][PDF] CTLA-4 expression by human tumor cells and its impact on immunotherapeutic strategies: a systematic review
F Abdulkhaleq, N Larossi, O Ogbonda… - Immuno-Oncology …, 2021 - aura.abdn.ac.uk
Background: Cancer is a leading cause of death worldwide and its development is closely
related to immune dysfunction. Immune checkpoint (IC) receptors maintain immune …
related to immune dysfunction. Immune checkpoint (IC) receptors maintain immune …
[HTML][HTML] TGFβ2 induces the Soluble Isoform of CTLA-4–Implications for CTLA-4 based checkpoint inhibitor antibodies in malignant Melanoma
Malignant melanoma is an aggressive form of cancer, which can be treated with anti-CTLA-4
and anti-PD-1 checkpoint inhibitor antibodies but while anti-CTLA-4 antibodies have clear …
and anti-PD-1 checkpoint inhibitor antibodies but while anti-CTLA-4 antibodies have clear …
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
S Laurent, P Queirolo, S Boero, S Salvi… - Journal of translational …, 2013 - Springer
Abstract Background CTLA-4 (Cytotoxic T lymphocyte antigen-4) is traditionally known as a
negative regulator of T cell activation. The blocking of CTLA-4 using human monoclonal …
negative regulator of T cell activation. The blocking of CTLA-4 using human monoclonal …
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome
N Krishnamurthy, D Nishizaki… - Therapeutic …, 2024 - journals.sagepub.com
Background: CTLA-4 impedes the immune system's antitumor response. There are two Food
and Drug Administration-approved anti-CTLA-4 agents–ipilimumab and tremelimumab–both …
and Drug Administration-approved anti-CTLA-4 agents–ipilimumab and tremelimumab–both …
Therapeutic use of anti-CTLA-4 antibodies
Targeting CTLA-4 represents a new type of immunotherapeutic approach, namely immune
checkpoint inhibition. Blockade of CTLA-4 by ipilimumab was the first strategy to achieve a …
checkpoint inhibition. Blockade of CTLA-4 by ipilimumab was the first strategy to achieve a …
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces
immune-mediated long-term control of metastatic melanoma in a fraction of patients …
immune-mediated long-term control of metastatic melanoma in a fraction of patients …